Improving Patient Selection for BPH Medical and Surgical Therapy Through a Deeper Understanding of Prostate Cellular and Molecular Biology.

INTEREXAMINER RELIABILITY OF TRANSRECTAL ULTRASOUND FOR ESTIMATING PROSTATE VOLUME

Personalized Medicine for the Management of Benign Prostatic Hyperplasia

Society of Interventional Radiology Research Reporting Standards for Prostatic Artery Embolization

SERUM PROSTATE SPECIFIC ANTIGEN IS A STRONG PREDICTOR OF FUTURE PROSTATE GROWTH IN MEN WITH BENIGN PROSTATIC HYPERPLASIA

Change in Sexual Function in Men with Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Associated with Long-Term Treatment with Doxazosin, Finasteride and Combined Therapy

Modifiable Risk Factors for Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms: New Approaches to Old Problems

Role of Antimuscarinics Combined With Alpha-blockers in the Management of Urinary Storage Symptoms in Patients With Benign Prostatic Hyperplasia: An Updated Systematic Review and Meta-analysis.

Commentary on "Integrative multiplatform molecular profiling of benign prostatic hyperplasia identifies distinct subtypes".

Response to Daily 10 Mg Alfuzosin Predicts Acute Urinary Retention and Benign Prostatic Hyperplasia Related Surgery in Men With Lower Urinary Tract Symptoms

The Relationship Between Testosterone-Replacement Therapy and Lower Urinary Tract Symptoms: A Systematic Review

Correlations of Urodynamic Changes With Changes in Symptoms and Well-being After Transurethral Resection of the Prostate

A Prospective Study of Lower Urinary Tract Symptoms and Erectile Dysfunction

Relationship of Symptoms of Prostatism to Commonly Used Physiological and Anatomical Measures of the Severity of Benign Prostatic Hyperplasia

To analyze the clinical features of benign prostate hyperplasia (BPH) with prostatitis and the role of prostatitis in progression of BPH. From July 2003 to Feb. 2009, 466 patients diagnosed BPH were enrolled in this study. Several items including age, history, IPSS, volume of prostate, prostatic special antigen (PSA) and related parameters, Qmax, acute urinary retention (AUR) and the way of treatment were analyzed. A total of 423 patients were diagnosed as BPH with prostatitis (90.77%, PS/BPH group), and 43 were BPH without prostatitis (9.23%, BPH group). Compared with the BPH group, patient's history of the PS/BPH group was longer, IPSS/QOL was increased, the volume of total prostate and transitional zone were larger, maximum flow rate was decreased and risk of AUR was increased, and the proportion of BPH-related surgery was higher.There was no significant difference in patient's age, tPSA, fPSA, f/tPSA, and PSAD between the 2 groups. Prostatitis may be one etiological factor for BPH. Patients with inflammation were more likely to progress clinically in terms of lower urinary tract symptoms (LUTS), acute urinary retention (AUR), or BPH-related surgery.

Benign prostatic hyperplasia (BPH) is a chronic and often progressive condition. It affects nearly three in four men by the seventh decade of life. Clinically, BPH is distinguished by progressive development of lower urinary tract symptoms (LUTS) even though not all patients with BPH develop LUTS. Retropubic simple prostatectomy was first described in 1945 and soon became the popular surgical management of BPH. Open prostatectomy was gradually replaced by transurethral resection of the prostate (TURP) as the standard surgical treatment of BPH. With the introduction of medical therapy in the 1980s, the standard treatment for patients with LUTS secondary to BPH shifted to pharmacotherapy with α-blockers and/or 5α-reductase inhibitors. This paradigm shift to pharmacological therapy led to a dramatic decrease in hospitalization for TURP throughout the 1990s. After more than 10 years of decrease in total BPH procedure rates, the trend was reversed after 2002 due to the marked increase in Minimally Invasive Surgical Techniques (MISTs) including transurethral microwave therapy, transurethral needle or ethanol ablation, high intensity frequency ultrasound, and laser resection/ablation as well as transurethral saline plasma vaporization. Unfortunately, all MISTs are associated with various degrees of sexual side effects, mainly ejaculatory dysfunction and erectile dysfunction. The UroLift System is newly approved technology by the FDA for BPH. This versatile implant self-sizes in the prostate and mechanically opens the prostatic urethra without causing any sexual side effects. This presentation will introduce this novel technology for the treatment of BPH.